Comments regarding ‘Plasma Levels of Matrix Metalloproteinase-9: A Possible Diagnostic Marker of Successful Endovascular Aneurysm Repair’  by Hinchliffe, R.J.
at SciVerse ScienceDirect
European Journal of Vascular and Endovascular Surgery 43 (2012) 173Contents lists availableEuropean Journal of Vascular and Endovascular Surgery
journal homepage: www.ejves.comInvited Commentary
Comments regarding ‘Plasma Levels of Matrix Metalloproteinase-9:
A Possible Diagnostic Marker of Successful Endovascular Aneurysm Repair’
R.J. Hinchliffe*
St George’s Vascular Institute, St George’s Healthcare NHS Trust, London SW17 0QT, United Kingdoma r t i c l e i n f o
Article history:
Received 7 November 2011
Accepted 8 November 2011
Available online 25 November 2011DOI of original article: 10.1016/j.ejvs.2011.10.014.
* Tel.: þ44 (0) 2087255823.
E-mail address: rhinchli@sgul.ac.uk.
1078-5884/$ e see front matter  2011 European So
doi:10.1016/j.ejvs.2011.11.004A more rational approach to the surveillance of patients with
endovascular aneurysm repair (EVAR) is urgently needed. Recent
publications have questioned the beneﬁt of surveillance and
demonstrated that signiﬁcant heterogeneity of surveillance
schedules exists among vascular units.1,2 Current imaging modali-
ties reliably identify endoleak and other stent-graft related
complications but are costly and some are potentially harmful. A
blood test which might predict complications or the need for
secondary interventions would be attractive.
Endoleak is an important but not the sole cause of late failure
of aortic stent-grafts. Iliac limb occlusion and stent-graft
migration are important predictors of secondary intervention.
Many endoleaks are entirely benign and the detection of these
benign (most frequently type 2) endoleaks will not improve
outcomes.
Previous studies have suggested that plasma levels of MMPmay
identify endoleak.3,4 This preliminary report is encouraging and
builds on these studies but does not tell us whether this approach
might be able to discriminate benign from dangerous endoleaks
nor whether MMP levels might change in individual patients
subsequent to the development or successful treatment of endo-
leak.5 Larger longitudinal studies, which the authors report to be
already underway, are required to conﬁrm these ﬁndings and
establish whether other demographic factors or complications
might impact upon the levels of various MMPs.ciety for Vascular Surgery. PublisheA more considered approach to EVAR surveillance is likely to
include targeted imaging of groups of patients at high risk of compli-
cations and secondary interventions. These factors have not yet been
clearly identiﬁed but are likely to include a combination of patient
demographics and aneurysm morphological factors. A blood test is
unlikely to become the sole biomarker of success following EVAR but
might conceivably be incorporated in to a risk stratiﬁcation model.References
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